<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811588</url>
  </required_header>
  <id_info>
    <org_study_id>CA5 - NIV COPD Registry EU</org_study_id>
    <nct_id>NCT02811588</nct_id>
  </id_info>
  <brief_title>Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation</brief_title>
  <acronym>HOmeVent</acronym>
  <official_title>Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation - HOmeVent Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CRI-The Clinical Research Institute GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of chronic respiratory disease, including chronic obstructive pulmonary
      disease (COPD), is increasing in industrialized countries. Over the next decade deaths from
      COPD are projected to increase by more than 30% and COPD will become the third leading cause
      of death worldwide by 2030. There is robust scientific evidence that non-invasive ventilation
      (NIV) therapy is an effective option for most COPD patients hospitalized with acute
      hypercapnic respiratory failure secondary to an acute disease exacerbation. More recently,
      NIV has been shown to significantly improve survival and quality of life in COPD patients
      with chronic stable hypercapnic disease. These data represent an important advance in the
      field, and indicate that usage of NIV in patients with chronic stable hypercapnic COPD should
      increase. Such an increase would be expected to improve patient outcomes and have a
      beneficial impact on the significant healthcare burden incurred by these patients. However,
      the proportion of stable COPD patients with chronic hypercapnia is unknown. In addition,
      using NIV at home to treat COPD patients with hypercapnic (type 2) respiratory failure has
      not often been considered previously and there is a paucity of data regarding NIV usage
      patterns over time in this setting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Prevalence of hypercapnia in patients with GOLD stage 3 and 4 COPD.</measure>
    <time_frame>July 2017</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of NIV use: NIV settings (modes, pressure, etc.), time to initiate NIV and compliance.</measure>
    <time_frame>July 2017</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">231</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Screening phase: normocapnic group</arm_group_label>
    <description>Normocapnic COPD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Screening phase: hypercapnic group</arm_group_label>
    <description>Hypercapnic COPD patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment phase: control group</arm_group_label>
    <description>Hypercapnic COPD patients in whom NIV is not indicated or who have contraindication(s) for, or refuse, NIV treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment phase: non-invasive ventilation group</arm_group_label>
    <description>Hypercapnic COPD patients in whom NIV is indicated and who accept NIV treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-invasive ventilation</intervention_name>
    <arm_group_label>Treatment phase: non-invasive ventilation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        GOLD stage 3 or 4 COPD
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  GOLD stage 3 or 4 COPD

          -  pCO2 value available not older than one month

          -  Ability to fully understand the study information and willing to give informed consent

        Exclusion Criteria:

          -  Existing treatment with NIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Koehnlein, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum St. Georg Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinik Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln</name>
      <address>
        <city>Cologne</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg - Robert Koch Klinik - Zentrum für Pneumologie</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://goldcopd.org/gold-reports/</url>
    <description>Global Initiative for Chronic Obstructive Lung Disease webpage</description>
  </link>
  <link>
    <url>http://www.who.int/respiratory/copd/burden/en/.</url>
    <description>World Health Organisation. Chronic Respiratory Diseases</description>
  </link>
  <reference>
    <citation>Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007 Sep 1;370(9589):765-73. Review.</citation>
    <PMID>17765526</PMID>
  </reference>
  <reference>
    <citation>Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, Simonneau G, Benito S, Gasparetto A, Lemaire F, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995 Sep 28;333(13):817-22.</citation>
    <PMID>7651472</PMID>
  </reference>
  <results_reference>
    <citation>Dreher M, Neuzeret PC, Windisch W, Martens D, Hoheisel G, Gröschel A, Woehrle H, Fetsch T, Graml A, Köhnlein T. Prevalence Of Chronic Hypercapnia In Severe Chronic Obstructive Pulmonary Disease: Data From The HOmeVent Registry. Int J Chron Obstruct Pulmon Dis. 2019 Oct 18;14:2377-2384. doi: 10.2147/COPD.S222803. eCollection 2019.</citation>
    <PMID>31695357</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

